NCCN Flash Updates: NCCN Guidelines®, NCCN Compendium®, and NCCN Templates Updated
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Kidney Cancer. These NCCN Guidelines® are currently available as Version 2.2021.
- Principles of Systemic Therapy (KID-C, 1 of 2)
- First-Line Therapy for Clear Cell Cancer Histology
- Preferred regimen: Favorable and poor/intermediate risk added, “Cabozantinib + nivolumab” as a category 2A recommendation.
Previous updates to the NCCN Guidelines for Kidney Cancer can be found in the UPDATES section of the current version.
NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Thyroid Carcinoma. These NCCN Guidelines are currently available as Version 3.2020.
- Papillary Carcinoma, Follicular Carcinoma, Hürthle Cell Carcinoma (PAP-10, PAP-11, FOLL-8, FOLL-9, HÜRT-8, and HÜRT-9)
- "Pralsetinib for patients with RET-fusion positive tumors" was added as a category 2A systemic therapy option for structurally persistent/recurrent locoregional or metastatic disease not amenable to radioactive iodine therapy.
- Medullary Carcinoma (MEDU-6 and MEDU-7)
- "Pralsetinib for patients with RET-mutation positive tumors" was added as a category 2A systemic therapy option (Preferred Regimens) for recurrent or persistent locoregional or distantly metastatic disease.
- Anaplastic Carcinoma (ANAP-A 2 of 3)
- "Pralsetinib for patients with RET-fusion positive tumors" was added as a category 2A systemic therapy option (Preferred Regimens) for metastatic disease.
- Reference for pralsetinib was added: "Subbiah et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-31, 2020)."
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Chronic Lymphocytic Leukemia to reflect the currently published NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma v2.2021.
- References have been updated for the following templates:
- CLL15: Alemtuzumab
- CLL17: PCR (Pentostatin/Cyclophosphamide + RiTUXimab)
- CLL22: Bendamustine + RiTUXimab
- CLL24: CHOP (Cyclophosphamide/DOXOrubicin/VinCRIStine/PredniSONE) + RiTUXimab
- CLL29: Alemtuzumab + RiTUXimab
- CLL42: Ofatumumab
- CLL64: Ibrutinib/Bendamustine + RiTUXimab
- CLL70: Venetoclax + RiTUXimab
- CLL71: Bendamustine + Ofatumumab
- CLL75: Acalabrutinib
- CLL81: Nivolumab
- CLL84: Duvelisib
- CLL86: Ibrutinib + RiTUXimab
- CLL88: Venetoclax + Obinutuzumab
- CLL89: Acalabrutinib + Obinutuzumab
- Changes to the Indication section have been made on the following templates:
- CLL2: Chlorambucil
- CLL3: Chlorambucil + RiTUXimab
- CLL12: FCR (Fludarabine/Cyclophosphamide) + RiTUXimab
- CLL14: FR (Fludarabine + RiTUXimab)
- CLL15: Alemtuzumab
- CLL17: PCR (Pentostatin/Cyclophosphamide + RiTUXimab)
- CLL22: Bendamustine + RiTUXimab
- CLL25: HDMP (High-Dose MethylPREDNISolone) + RiTUXimab
- CLL29: Alemtuzumab + RiTUXimab
- CLL31: RiTUXimab
- CLL35: Reduced-dose PCR (Pentostatin/Cyclophosphamide) + RiTUXimab
- CLL36: Reduced-dose FCR (Fludarabine/Cyclophosphamide) + RiTUXimab
- CLL38: Dose-Dense RiTUXimab
- CLL42: Ofatumumab
- CLL54: Lenalidomide
- CLL55: Lenalidomide + RiTUXimab
- CLL58: Ibrutinib
- CLL59: Chlorambucil + Obinutuzumab
- CLL60: Idelalisib + RiTUXimab
- CLL61: Idelalisib
- CLL62: Obinutuzumab
- CLL64: Ibrutinib/Bendamustine + RiTUXimab
- CLL65: Idelalisib/Bendamustine + RiTUXimab
- CLL66: Venetoclax
- CLL67: FC (Fludarabine/Cyclophosphamide) + Ofatumumab
- CLL70: Venetoclax + RiTUXimab
- CLL71: Bendamustine + Ofatumumab
- CLL74: Bendamustine + Obinutuzumab
- CLL75: Acalabrutinib
- CLL81: Nivolumab
- CLL84: Duvelisib
- Emetic Risk has been updated on the following template:
- CLL68: Ofatumumab Maintenance
- Changes to the Chemotherapy Regimen section have been made on the following templates:
- CLL17: PCR (Pentostatin/Cyclophosphamide + RiTUXimab)
- CLL25: HDMP (High-Dose MethylPREDNISolone) + RiTUXimab
- CLL60: Idelalisib + RiTUXimab
- CLL73a: HyperCVAD (Cyclophosphamide/VinCRIStine/DOXOrubicin/Dexamethasone) + RiTUXimab (Cycle A) alternating with High-Dose Methotrexate/Cytarabine + RiTUXimab (Cycle B) – HyperCVAD + RiTUXimab (Cycle A) Course
- CLL80: Pembrolizumab
- Notes in the Supportive Care section have been updated for the following templates:
- CLL3: Chlorambucil + RiTUXimab
- CLL58: Ibrutinib
- CLL60: Idelalisib + RiTUXimab
- CLL61: Idelalisib
- CLL65: Idelalisib/Bendamustine + RiTUXimab
- Notes in the Monitoring and Hold Parameters section have been updated for the following templates:
- CLL58: Ibrutinib
- CLL64: Ibrutinib/Bendamustine + RiTUXimab
- CLL65: Idelalisib/Bendamustine + RiTUXimab
- Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
- Cyclophosphamide
- Etoposide
- Ibrutinib
- RiTUXimab
NCCN has updated the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) to reflect recommendations within the following NCCN Guidelines:
- Management of Immunotherapy-Related Toxicities version 1.2020
- Management of Immunotherapy-Related Toxicities version 1.2021
- B-Cell Lymphomas Version 1.2021
- Colorectal Cancer Screening version 2.2020
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.